Astellas Oncology uses a broad range of scientific thinking for our investigational pipeline. Drug candidates for advanced or resistant disease are our priority.
We utilize the latest science, exploring new technologies, modalities, and biologics.
The safety and efficacy of these agents under investigation have not been established for the use(s) being considered. There is no guarantee that the agent will receive regulatory approval or become commercially available for the use being investigated.
| Generic Name Code No. (Brand Name) |
Classification | Target Disease | Phase | Licensor |
|---|---|---|---|---|
| Enfortumab vedotin ASG-22ME (PADCEV) |
Nectin-4 targeted ADC | Metastatic urothelial cancer, previously untreated (first line; combo with pembrolizumab) |
3 | In-house [Co-development with Seagen] |
| Muscle-invasive bladder cancer (combo with pembrolizumab) |
3 | |||
| Other solid tumors | 2 | |||
| Non-muscle-invasive bladder cancer | 1 | |||
| Gilteritinib ASP2215 (XOSPATA) |
FLT3 inhibitor | Post-chemotherapy maintenance acute myeloid leukemia |
3 | In-house |
| Post-hematopoietic stem cell transplant maintenance acute myeloid leukemia |
3 | |||
| Newly diagnosed acute myeloid leukemia with high intensity induction of chemotherapy |
3 | |||
| Newly diagnosed acute myeloid leukemia with low intensity induction of chemotherapy |
1 | |||
| Acute myeloid leukemia in pediatric patients | 3 | |||
| Zolbetuximab< IMAB362 |
Anti-Claudin 18.2 monoclonal antibody |
Gastric and gastroesophageal junction adenocarcinoma |
Filed | In-house (Ganymed) |
| Pancreatic adenocarcinoma | 2 | |||
| ASP1570 | DGKζ inhibitor | Cancer | 1 | In-house |
| ASP2138 | Anti-Claudin 18.2 and anti-CD3 bispecific antibody |
Cancer | 1 | Xencor [Discovered through collaborative research] |
| ASP2074 | Anti-TSPAN8 and anti-CD3 bispecific antibody |
Cancer | 1 | In-house |
| ASP1002 | Bispecific antibody | Cancer | 1 | In-house |
| ASP3082 | KRAS G12D degrader | Cancer | 1 | In-house |
The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China (as of February 2024).
Our clinical research is focused on therapies for hard-to-treat cancers.
Discover clinical trials that might be appropriate for your patients.
You are now leaving www.astellasoncology.com. The website you are linking to is neither owned nor controlled by Astellas. Astellas is not responsible for the content or services on this site.
